title: Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy.
abstract: Noonan syndrome (NS) is an autosomal dominant developmental disorder caused by mutations in the RAS-MAPK signaling pathway that is well known for its relationship with oncogenesis. An 8.1-fold increased risk of cancer in Noonan syndrome has been reported, including childhood leukemia and solid tumors. The same study found a patient with a dysembryoplastic neuroepithelial tumor (DNET) and suggested that DNET tumors are associated with NS. Herein we report an 8-year-old boy with genetically confirmed NS and a DNET. Literature review identified eight other reports, supporting the association between NS and DNETs. The review also ascertained 13 non-DNET brain tumors in individuals with NS, bringing to 22 the total number of NS patients with brain tumors. Tumor growth while receiving growth hormone (GH) occurred in our patient and one other patient. It is unknown whether the development or progression of tumors is augmented by GH therapy, however there is concern based on epidemiological, animal and in vitro studies. This issue was addressed in a 2015 Pediatric Endocrine Society report noting there is not enough data available to assess the safety of GH therapy in children with neoplasia-predisposition syndromes. The authors recommend that GH use in children with such disorders, including NS, be undertaken with appropriate surveillance for malignancies. Our case report and literature review underscore the association of NS with CNS tumors, particularly DNET, and call attention to the recommendation that clinicians treating NS patients with GH do so with awareness of the possibility of increased neoplasia risk.
authors.affiliation: University of California, Davis, School of Medicine, Sacramento, California.
authors.forename: Geoffrey D
authors.initials: GD
authors.lastname: McWilliams
authors.affiliation: University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
authors.forename: Karen
authors.initials: K
authors.lastname: SantaCruz
authors.affiliation: University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
authors.forename: Blaine
authors.initials: B
authors.lastname: Hart
authors.affiliation: University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
authors.forename: Carol
authors.initials: C
authors.lastname: Clericuzio
mesh_terms: D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000139:chemically induced*; D002648:Child; D005260:Female; D019382:Human Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018302:Neoplasms, Neuroepithelial / Q000139:chemically induced*; D009634:Noonan Syndrome / Q000188:drug therapy* / Q000235:genetics*; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Q000235:genetics*; D012306:Risk; D055815:Young Adult
chemical_list: D019382:Human Growth Hormone; C516724:PTPN11 protein, human; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11
keywords: DNET; Noonan syndrome; Noonan syndrome with multiple lentigines; PTPN11; ganglioglioma; growth hormone